Alnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini
Company Announcements

Alnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini

Alnylam Pharmaceuticals (ALNY) has issued an update.

Alnylam Pharmaceuticals has finalized a separation and release agreement with its former Executive Vice President, Indrani L. Franchini, effective March 1, 2024. Franchini will receive severance pay, a lump sum equivalent to her potential 2023 annual incentive, healthcare premium contributions, outplacement services, and legal fee reimbursement. Additionally, she has entered a one-year consulting contract with the company, during which her unvested equity will continue to vest, and she will be compensated for any extra consulting hours. Her equity awards will also align with active employees’ terms in case of a company control change.

Find detailed analytics on ALNY stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlnylam price target raised to $307 from $295 at BofA
TheFlyAlnylam updated ‘checks nearly all the boxes,’ says Barclays
TheFlyDell, Marvell get AI boost to beat expectations: Morning Buzz
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App